Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 4/20 | 0.34 |
| ▸ | RAB9A | P51151 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | AKT2 | P31751 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9956367 | 0.81 | RAB9A (0.42) | SMN1; SMN2ALDH1A1MAPTL3MBTL1NPC1 | |
| SCHEMBL9954131 | 0.80 | NPC1 (0.36) | MAPK13MAPK12MAPK11MAPK14SMN1; SMN2 | |
| SCHEMBL9955349 | 0.78 | NOTUM (0.39) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL9955323 | 0.78 | ESR2 (0.44) | SMN1; SMN2ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL613320 | 0.77 | NR4A2 (0.42) | MAPK13MAPK12MAPK11MAPK14SMN1; SMN2 | |
| SCHEMBL3054439 | 0.75 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1L3MBTL1NPC1RAB9A | |
| SCHEMBL4724450 | 0.75 | NPC1 (0.39) | SMN1; SMN2ALDH1A1MAPTL3MBTL1NPC1 | |
| SCHEMBL9956338 | 0.75 | NPC1 (0.39) | SMN1; SMN2ALDH1A1L3MBTL1NPC1RAB9A | |
| SCHEMBL8848399 | 0.72 | KDM4E (0.37) | SMN1; SMN2ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL4511405 | 0.71 | PTGS1 (0.46) | BRD4BRD2MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | BROWN REBECCA ELIZABETH | 2009-12-03 | — | — | US | disclosed |
| EP-1881988-A1 | 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES MODULATING THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2008-01-30 | — | — | EP | disclosed |
| WO-2008001134-A1 | 1,2,3,8,9,9A-HEXAHYDRO-7H-BENZO(DE)-1,7-NAPHTHYRIDIN-7-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-01-03 | — | — | WO | disclosed |
| US-20070208021-A1 | Phenoxyacetic Acid Derivatives and Drug Comprising The Same | DAIICHI PHARMACEUTICAL CO., LTD. | 2007-09-06 | — | — | US | disclosed |
| EP-1731513-A1 | PHENOXYACETIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-13 | — | — | EP | disclosed |
| WO-2006122200-A1 | 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES MODULATING THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-16 | — | — | WO | disclosed |
| CN-1173776-C | High-throughput screening assay systems in microscale fluidic devices | �����������Ǯ�������� | 2004-11-03 | — | — | CN | disclosed |
| CN-1262629-A | High throughput screening assay system in microscale fluidic devices | CALIPER TECHN CORP (US) | 2000-08-09 | — | — | CN | disclosed |
| US-6030975-A | ANTAGONIST OF ENDOTHELINS, I.E. INHIBITION OF BINDING WITH RECEPTOR; ANTITUMOR AND -CARCINOGENIC AGENTS; SIDE EFFECT REDUCTION | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
| US-5840722-A | ADMINISTERING TO INHIBIT ENDOTHELIN RECEPTORS | BASF AKTIENGESELLSCHAFT (DE) | 1998-11-24 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5558904-A | Electroluminescent devices containing a conjugated polymer obtained via halogen precursor route chemistry | XEROX CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0695296-A1 | 3-(HETERO)ARYLOXY(THIO) CARBOXYLIC ACID DERIVATIVES, METHOD OF PREPARING THEM AND INTERMEDIATES USED IN THEIR PREPARATION | BASF AKTIENGESELLSCHAFT (DE) | 1996-02-07 | — | — | EP | disclosed |
| WO-1994025443-A1 | 3-(HETERO)ARYLOXY(THIO) CARBOXYLIC ACID DERIVATIVES, METHOD OF PREPARING THEM AND INTERMEDIATES USED IN THEIR PREPARATION | BASF AKTIENGESELLSCHAFT (DE) | 1994-11-10 | — | — | WO | disclosed |
| EP-0566020-A1 | Benzimidazoles, pharmaceutical compositions thereof and processes for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-10-20 | — | — | EP | disclosed |
| US-4374749-A | Index-matched phosphor scintillator structures | GENERAL ELECTRIC COMPANY (US) | 1983-02-22 | — | — | US | disclosed |
| EP-0022768-A1 | MACROMOLECULAR ENVIRONMENT CONTROL IN SPECIFIC RECEPTOR ASSAYS. | SYVA CO (US) | 1981-01-28 | — | — | EP | disclosed |
| EP-0022768-A4 | MACROMOLECULAR ENVIRONMENT CONTROL IN SPECIFIC RECEPTOR ASSAYS. | SYVA CO (US) | 1980-08-18 | — | — | EP | disclosed |
| WO-1979000882-A1 | MACROMOLECULAR ENVIRONMENT CONTROL IN SPECIFIC RECEPTOR ASSAYS | SYVA CO (US) | 1979-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | TRPV1, TRPV2, TRPV4 | BRD4 508/4885BRD2 738/4885TDO2 1758/4885 |
| US-20070208021-A1 | Phenoxyacetic Acid Derivatives and Drug Comprising The Same | PPARA, PPARG, PPARD | BRD4 713/4885BRD2 1598/4885TDO2 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.